Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
ZIOP's Cash to Debt is ranked higher than
93% of the 896 Companies
in the Global Biotechnology industry.

( Industry Median: 171.30 vs. ZIOP: No Debt )
ZIOP' s 10-Year Cash to Debt Range
Min: No Debt   Max: No Debt
Current: No Debt

Equity to Asset 0.69
ZIOP's Equity to Asset is ranked higher than
73% of the 759 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. ZIOP: 0.69 )
ZIOP' s 10-Year Equity to Asset Range
Min: -17   Max: 0.69
Current: 0.69

-17
0.69
Interest Coverage No Debt
ZIOP's Interest Coverage is ranked higher than
74% of the 425 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ZIOP: No Debt )
ZIOP' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 3
Z-Score: 1.49
M-Score: -0.97
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -7214.13
ZIOP's Operating margin (%) is ranked lower than
51% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: -66.98 vs. ZIOP: -7214.13 )
ZIOP' s 10-Year Operating margin (%) Range
Min: -12771.13   Max: -1333.33
Current: -7214.13

-12771.13
-1333.33
Net-margin (%) -7138.38
ZIOP's Net-margin (%) is ranked lower than
51% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: -56.37 vs. ZIOP: -7138.38 )
ZIOP' s 10-Year Net-margin (%) Range
Min: -12016.5   Max: -1333.33
Current: -7138.38

-12016.5
-1333.33
ROE (%) -115.64
ZIOP's ROE (%) is ranked higher than
53% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: -21.87 vs. ZIOP: -115.64 )
ZIOP' s 10-Year ROE (%) Range
Min: -374.4   Max: -27.22
Current: -115.64

-374.4
-27.22
ROA (%) -79.59
ZIOP's ROA (%) is ranked higher than
54% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: -18.90 vs. ZIOP: -79.59 )
ZIOP' s 10-Year ROA (%) Range
Min: -4000   Max: -15.38
Current: -79.59

-4000
-15.38
ROC (Joel Greenblatt) (%) -7205.12
ZIOP's ROC (Joel Greenblatt) (%) is ranked higher than
52% of the 872 Companies
in the Global Biotechnology industry.

( Industry Median: -196.35 vs. ZIOP: -7205.12 )
ZIOP' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -9701.98   Max: -2368.88
Current: -7205.12

-9701.98
-2368.88
EBITDA Growth (%) 7.60
ZIOP's EBITDA Growth (%) is ranked higher than
86% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -10.30 vs. ZIOP: 7.60 )
ZIOP' s 10-Year EBITDA Growth (%) Range
Min: -30.4   Max: 88.9
Current: 7.6

-30.4
88.9
EPS Growth (%) -2.40
ZIOP's EPS Growth (%) is ranked higher than
81% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: -12.80 vs. ZIOP: -2.40 )
ZIOP' s 10-Year EPS Growth (%) Range
Min: -38.5   Max: 86.1
Current: -2.4

-38.5
86.1
» ZIOP's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

ZIOP Guru Trades in Q1 2013

Jean-Marie Eveillard 200,000 sh (New)
Kyle Bass 316,987 sh (New)
Paul Tudor Jones 63,100 sh (New)
Steven Cohen 750,000 sh (New)
» More
Q2 2013

ZIOP Guru Trades in Q2 2013

Chuck Royce 660,000 sh (New)
Steven Cohen 888,000 sh (+18.4%)
Kyle Bass Sold Out
Jean-Marie Eveillard Sold Out
Paul Tudor Jones 25,100 sh (-60.22%)
» More
Q3 2013

ZIOP Guru Trades in Q3 2013

Steven Cohen Sold Out
Chuck Royce 576,000 sh (-12.73%)
Paul Tudor Jones 18,200 sh (-27.49%)
» More
Q4 2013

ZIOP Guru Trades in Q4 2013

Paul Tudor Jones 27,211 sh (+49.51%)
Chuck Royce 366,000 sh (-36.46%)
» More
» Details

Insider Trades

Latest Guru Trades with ZIOP

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Jean-Marie Eveillard 2013-06-30 Sold Out $1.52 - $2.621 $ 3.3480%0
Jean-Marie Eveillard 2013-03-31 New Buy$1.72 - $5.71 $ 3.34-24%200000
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about ZIOPHARM Oncology, Inc.

Bass’ New Buy – ZIOPHARM Oncology Inc.
The founder of Hayman Advisors Kyle Bass made a fortune during the sub-prime crisis, and today he does not like Japan and likes structured mortgages, housing, gold and U.S. stocks. His U.S. portfolio contains eight stocks – one of them new. With seven stocks sold out, his portfolio had 47% quarter-over-quarter turnover and a value of $165 million. Read more...
The Far-Off Four, 52-week Lows Held by Gurus
This week the GuruFocus 52-week low screener reveals the “Far-Off Four,” meaning four stocks that are among the farthest off-high: Read more...

Ratios

vs
industry
vs
history
P/B 6.90
ZIOP's P/B is ranked lower than
54% of the 791 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. ZIOP: 6.90 )
ZIOP' s 10-Year P/B Range
Min: 2.5   Max: 121.3
Current: 6.9

2.5
121.3
P/S 357.14
ZIOP's P/S is ranked lower than
90% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 10.27 vs. ZIOP: 357.14 )
ZIOP' s 10-Year P/S Range
Min: 0   Max: 622
Current: 357.14

0
622
EV-to-EBIT 21.30
ZIOP's EV-to-EBIT is ranked higher than
51% of the 468 Companies
in the Global Biotechnology industry.

( Industry Median: 20.00 vs. ZIOP: 21.30 )
ZIOP' s 10-Year EV-to-EBIT Range
Min: 6.5   Max: 9.4
Current: 21.3

6.5
9.4

Valuation & Return

vs
industry
vs
history
Price/Net Cash 7.30
ZIOP's Price/Net Cash is ranked higher than
60% of the 477 Companies
in the Global Biotechnology industry.

( Industry Median: 9.30 vs. ZIOP: 7.30 )
ZIOP' s 10-Year Price/Net Cash Range
Min: 2.23   Max: 9.43
Current: 7.3

2.23
9.43
Price/Net Current Asset Value 7.30
ZIOP's Price/Net Current Asset Value is ranked higher than
60% of the 525 Companies
in the Global Biotechnology industry.

( Industry Median: 9.60 vs. ZIOP: 7.30 )
ZIOP' s 10-Year Price/Net Current Asset Value Range
Min: 2.23   Max: 9.43
Current: 7.3

2.23
9.43
Price/Tangible Book 6.80
ZIOP's Price/Tangible Book is ranked lower than
51% of the 736 Companies
in the Global Biotechnology industry.

( Industry Median: 6.00 vs. ZIOP: 6.80 )
ZIOP' s 10-Year Price/Tangible Book Range
Min: 1.81   Max: 8.86
Current: 6.8

1.81
8.86
Forward Rate of Return (Yacktman) -1.44
ZIOP's Forward Rate of Return (Yacktman) is ranked higher than
84% of the 669 Companies
in the Global Biotechnology industry.

( Industry Median: -9.87 vs. ZIOP: -1.44 )
ZIOP' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 48.5   Max: 212.2
Current: -1.44

48.5
212.2

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:WEK.Germany
ZIOPHARM Oncology, Inc. is a Delaware Corporation originally incorporated in Colorado in September 1998 under the name Net Escapes, Inc. and later changed its name to "EasyWeb, Inc." in February 1999. Following reincorporation in Delaware in May 2005 under the same name, we completed a "reverse" acquisition of privately held ZIOPHARM, Inc., a Delaware corporation on September 13, 2005. It is a biopharmaceutical company engaged in the development and commercialization of small molecule and synthetic biology approaches to new cancer therapies. Palifosfamide (Zymafos or ZIO-201) is a novel DNA cross-linker that in preclinical study has been shown to bypass resistance mediated by aldehyde dehydrogenase (ALDH), in addition to conferring a favorable toxicity profile compared to other in-class agents. Palifosfamide, administered intravenously, is currently in a randomized, double-blinded, placebo-controlled Phase 3 trial for the treatment of metastatic soft tissue sarcoma in the front-line setting. The Company is also currently completing a Phase 1 study of palifosfamide in combination with standard of care for addressing small cell lung cancer; an investigational new drug application has been accepted for the oral form of palifosfamide. DNA-based therapeutics (synthetic biology), in partnership with Intrexon Corporation, include two clinical-stage product candidates, both of which are DNA IL-12 using the RheoSwitch Therapeutic System to be turned on/off by an oral activator ligand and are currently in Phase 1. Additionally, multiple INDs are expected in the next 12-24 months resulting from preclinical and discovery work underway to advance multiple antibody, immunotoxin, and protein decoy candidates, systemic delivery and a next generation RheoSwitch Therapeutic System. Indibulin (Zybulin or ZIO-301) is a novel, oral tubulin binding agent that is expected to have several potential benefits including oral dosing, application in multi-drug resistant tumors, no neuropathy and a quite tolerable toxicity profile. It is currently being studied in Phase 1/2 in metastatic breast cancer. Darinaparsin (Zinapar or ZIO-101) is a novel mitochondrial- and hedgehog-targeted agent (organic arsenic) currently in a solid tumor Phase 1 study with oral administration and has been developed intravenously for the treatment of relapsed peripheral T-cell lymphoma. ZIOPHARM's operations are located in Boston, MA, Germantown, MD and New York City.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide